Noninvasive imaging for the evaluation of JAK inhibitors efficacy in the management of facial vitiligo.

Maria Elisabetta Greco¹, Francesca Feresin¹, Alberto di Caro¹, Francesca Paola Sasso¹, Ilaria Proietti², Luigi Angelo Fiorito³, Nicola Perrotta³, Giovanni Pellacani¹, Concetta Potenza², Steven Paul Nisticò¹, Annunziata Dattola¹

¹Dermatology Unit, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome, Italy.

²Unit of Dermatology, Department of Medical-Surgical Science and Biotechnologies, Sapienza University of Rome, A. Fiorini Hospital, Terracina, Latina, Italy.

³Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy.

PubMed DOI

Abstract

INTRODUCTION: Vitiligo is an acquired depigmenting disorder characterized by white macules resulting from the loss of functional melanocytes. MATERIAL AND METHODS: This multicenter, real-life observational study evaluated the efficacy of topical Ruxolitinib (15 mg/g) in 100 patients with non-segmental facial vitiligo treated twice daily for three months, combining clinical scales and noninvasive…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.